Effect of Fully Blocking Type 1 Angiotensin Receptor on Target Organ Damage of Postmenopausal Hypertensive Women

NCT ID: NCT03432468

Last Updated: 2018-03-13

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 102 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-04-01
• Study Completion Date: 2019-08-01

Brief Summary

This study compared the improvements of blood pressure levels, left ventricular hypertrophy, left ventricular diastolic function, vascular function and cognitive function between postmenopausal hypertensive women and age-matched hypertensive male patients through the evaluation of the effects of fully blocked AT1 receptor by valsartan. Additionally, the differences of the above indexes between the patients who were fully blocked AT1 receptor by valsartan and the patients who were treated with a single dose of valsartan treatment were assessed, so as to provide theory basis for clinical treatment of postmenopausal hypertensive women.

Conditions

Hypertension

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

postmenopausal hypertensive women

Group Type: ACTIVE_COMPARATOR

Valsartan 1

Intervention Type: DRUG

the high dose of valsartan

Valsartan 80 mg

Intervention Type: DRUG

a single dose of valsartan

age-matched hypertensive male patients

Group Type: PLACEBO_COMPARATOR

Valsartan 1

Intervention Type: DRUG

the high dose of valsartan

Interventions

Valsartan 1

the high dose of valsartan

Intervention Type: DRUG

Valsartan 80 mg

a single dose of valsartan

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Clinical diagnosis of hypertension
• Women are all postmenopausal
• Must provide written informed consent

Exclusion Criteria

• Secondary hypertension
• Coronary disease
• Heart failure
• Arterial fibrillation
• Previous myocardial infarction
• Previous stroke
• Malignant disease
• Kidney failure
• Liver failure
• Neoplastic disease
• Severe neurological diseases
• Severe metabolic or organic decompensation
• Refuse to sign the informed consent form

• Minimum Eligible Age: 40 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

LanZhou University

OTHER

Sponsor Role: lead

Responsible Party

Jing Yu

Principal Investigator

Responsibility Role: PRINCIPAL_INVESTIGATOR

Other Identifiers

LanZhouU

Identifier Type: -

Identifier Source: org_study_id